Pre-made Blosozumab benchmark antibody ( Whole mAb, anti-SOST therapeutic antibody, Anti-CDD/DAND6/VBCH Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Blosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density. Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-076-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Blosozumab biosimilar, Whole mAb, Anti-SOST Antibody: Anti-CDD/DAND6/VBCH therapeutic antibody
INN Name	Blosozumab
Target	SOST
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	Eli Lilly
Conditions Approved	na
Conditions Active	Postmenopausal osteoporosis
Conditions Discontinued	na
Development Tech	na